Inhibikase Therapeutics's total assets for Q2 2024 were $8.83M, a decrease of -20.25% from the previous quarter. IKT total liabilities were $3.73M for the fiscal quarter, a -13.08% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.